Synopsis
Synopsis
0
CEP/COS
0
JDMF
0
VMF
0
FDF
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. Hki 272
2. Hki-272
3. Hki272
4. N-(4-(3-chloro-4-(2-pyridinylmethoxy)anilino)-3-cyano-7-ethoxy-6-quinolyl)-4-(dimethylamino)-2-butenamide
5. Neratinib
6. Nerlynx
1. 915942-22-2
2. Neratinib Maleate [mi]
3. Neratinib (maleate)
4. 9rm7xy23zs
5. 915942-22-2 (maleate)
6. (e)-n-(4-((3-chloro-4-(pyridin-2-ylmethoxy)phenyl)amino)-3-cyano-7-ethoxyquinolin-6-yl)-4-(dimethylamino)but-2-enamide Maleate
7. 2-butenamide, N-(4-((3-chloro-4-(2-pyridinylmethoxy)phenyl)amino)-3-cyano-7-ethoxy-6-quinolinyl)-4-(dimethylamino)-, (2e)-, (2z)-2-butenedioate (1:1)
8. Hki272
9. (2e)-n-[4-[[3-chloro-4-[(pyridin-2-yl)methoxy]phenyl]amino]-3-cyano-7-ethoxyquinolin-6-yl]-4-(dimethylamino)but-2-enamide Maleate
10. Unii-9rm7xy23zs
11. Hki-272 Maleate
12. Nerlynx (tn)
13. Schembl2180998
14. Chembl3989921
15. Neratinib Maleate Anhydrous
16. Dtxsid801027861
17. Neratinib Maleate [who-dd]
18. (z)-but-2-enedioic Acid;(e)-n-[4-[3-chloro-4-(pyridin-2-ylmethoxy)anilino]-3-cyano-7-ethoxyquinolin-6-yl]-4-(dimethylamino)but-2-enamide
19. Amy16542
20. Bcp28677
21. Hy-32721b
22. Neratinib Maleate [orange Book]
23. Bn160240
24. Ds-19892
25. Cs-0030935
26. D10898
27. D71134
28. Q27272985
Molecular Weight | 673.1 g/mol |
---|---|
Molecular Formula | C34H33ClN6O7 |
Hydrogen Bond Donor Count | 4 |
Hydrogen Bond Acceptor Count | 12 |
Rotatable Bond Count | 13 |
Exact Mass | 672.2099251 g/mol |
Monoisotopic Mass | 672.2099251 g/mol |
Topological Polar Surface Area | 187 Ų |
Heavy Atom Count | 48 |
Formal Charge | 0 |
Complexity | 1000 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 0 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 2 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 2 |
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
Related Excipient Companies
Excipients by Applications
Market Place
Patents & EXCLUSIVITIES
ABOUT THIS PAGE
A Neratinib manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Neratinib, including repackagers and relabelers. The FDA regulates Neratinib manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Neratinib API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Neratinib manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Neratinib supplier is an individual or a company that provides Neratinib active pharmaceutical ingredient (API) or Neratinib finished formulations upon request. The Neratinib suppliers may include Neratinib API manufacturers, exporters, distributors and traders.
click here to find a list of Neratinib suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Neratinib DMF (Drug Master File) is a document detailing the whole manufacturing process of Neratinib active pharmaceutical ingredient (API) in detail. Different forms of Neratinib DMFs exist exist since differing nations have different regulations, such as Neratinib USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Neratinib DMF submitted to regulatory agencies in the US is known as a USDMF. Neratinib USDMF includes data on Neratinib's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Neratinib USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Neratinib suppliers with USDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a Neratinib Drug Master File in Korea (Neratinib KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Neratinib. The MFDS reviews the Neratinib KDMF as part of the drug registration process and uses the information provided in the Neratinib KDMF to evaluate the safety and efficacy of the drug.
After submitting a Neratinib KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Neratinib API can apply through the Korea Drug Master File (KDMF).
click here to find a list of Neratinib suppliers with KDMF on PharmaCompass.
A Neratinib written confirmation (Neratinib WC) is an official document issued by a regulatory agency to a Neratinib manufacturer, verifying that the manufacturing facility of a Neratinib active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Neratinib APIs or Neratinib finished pharmaceutical products to another nation, regulatory agencies frequently require a Neratinib WC (written confirmation) as part of the regulatory process.
click here to find a list of Neratinib suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Neratinib as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Neratinib API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Neratinib as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Neratinib and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Neratinib NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Neratinib suppliers with NDC on PharmaCompass.
Neratinib Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Neratinib GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Neratinib GMP manufacturer or Neratinib GMP API supplier for your needs.
A Neratinib CoA (Certificate of Analysis) is a formal document that attests to Neratinib's compliance with Neratinib specifications and serves as a tool for batch-level quality control.
Neratinib CoA mostly includes findings from lab analyses of a specific batch. For each Neratinib CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Neratinib may be tested according to a variety of international standards, such as European Pharmacopoeia (Neratinib EP), Neratinib JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Neratinib USP).
LOOKING FOR A SUPPLIER?